Impact of Concomitant Cardiovascular Therapies on Efficacy and Safety of Relugolix vs Leuprolide: Subgroup Analysis from HERO Study in Advanced Prostate Cancer

INTRODUCTION: Cardiovascular (CV) events are the leading cause of death in prostate cancer. Men with prostate cancer are likely to have CV risk factors and use CV-related concomitant medications. In the phase 3 HERO study, a 54% lower incidence of major adverse cardiac events was reported in men tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Shore, Neal D., Mehlhaff, Bryan A., Cookson, Michael S., Saltzstein, Daniel R., Tutrone, Ronald, Brown, Bruce, Lu, Sophia, Fallick, Mark, Hanson, Sarah, Saad, Fred
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10567896/
https://www.ncbi.nlm.nih.gov/pubmed/37713020
http://dx.doi.org/10.1007/s12325-023-02634-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10567896/
https://www.ncbi.nlm.nih.gov/pubmed/37713020
http://dx.doi.org/10.1007/s12325-023-02634-7

Ejemplares similares